---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092128"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-08-06T21:15:10+00:00"
generated_at: "2026-08-06T21:16:08.706662+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor

## Summary
- Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.
- Commission of 3.0% of gross proceeds payable to agents; no minimum offering amount required.
- Replaces prior $100M ATM agreement dated February 27, 2025; new agreement has no stated maximum.
- Shares sold under existing Form S-3 registration statement; Company retains discretion on timing and size.

## SEC filing metadata
- accession: 0001104659-26-092128
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-08-06T21:15:10+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/0001104659-26-092128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092128
- JSON: https://secwatch.observer/filing/0001104659-26-092128.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.